Cargando…

The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?

Purpose: To evaluate the MOLES system for identifying malignancy in melanocytic choroidal tumors in patients treated for choroidal melanoma. Methods: Records of 615 patients treated for choroidal melanoma between January 2017 and December 2019 were reviewed. Patients were excluded if iris and/or cil...

Descripción completa

Detalles Bibliográficos
Autores principales: Roelofs, Kelsey A., O’Day, Roderick, Al Harby, Lamis, Arora, Amit K., Cohen, Victoria M.L., Sagoo, Mandeep S., Damato, Bertil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281649/
https://www.ncbi.nlm.nih.gov/pubmed/32455720
http://dx.doi.org/10.3390/cancers12051311
_version_ 1783543969507966976
author Roelofs, Kelsey A.
O’Day, Roderick
Al Harby, Lamis
Arora, Amit K.
Cohen, Victoria M.L.
Sagoo, Mandeep S.
Damato, Bertil
author_facet Roelofs, Kelsey A.
O’Day, Roderick
Al Harby, Lamis
Arora, Amit K.
Cohen, Victoria M.L.
Sagoo, Mandeep S.
Damato, Bertil
author_sort Roelofs, Kelsey A.
collection PubMed
description Purpose: To evaluate the MOLES system for identifying malignancy in melanocytic choroidal tumors in patients treated for choroidal melanoma. Methods: Records of 615 patients treated for choroidal melanoma between January 2017 and December 2019 were reviewed. Patients were excluded if iris and/or ciliary body involvement (106 patients), inadequate fundus photography (26 patients), no images available for review (21 patients) and/or treatment was not primary (11 patients). Demographic data and AJCC TNM Stage were collected. Color fundus and autofluorescence photographs (FAF), optical coherence tomography (OCT) and B-scan ultrasounds were prospectively reviewed. MOLES scores were assigned according to five criteria: mushroom shape, orange pigment, large size, enlarging tumor and subretinal fluid. Results: A total of 451 patients (mean age, 63.9 ± 13.9 years) were included. At treatment, mean largest basal tumor diameter (LBD) and thickness were 10.3 ± 2.8 mm (range, 3.0–23.0) and 4.3 mm (range, 1.0–17.0). All but one (0.2%) had MOLES scores of ≥3. Eighty-two patients were treated after surveillance lasting a mean of 1.5 years. Initially, most (63/82; 76.8%) had a MOLES score ≥ 3. Importantly, none of the 451 tumors had a score of <2, and as such, the MOLES protocol would have indicated referral to an ocular oncologist for 100% of patients. Conclusion: The MOLES scoring system is a sensitive (99.8%) tool for indicating malignancy in melanocytic choroidal tumors (MOLES ≥ 3). If the examining practitioner can recognize the five features suggestive of malignancy, MOLES is a safe tool to optimize referral of melanocytic choroidal tumors for specialist care.
format Online
Article
Text
id pubmed-7281649
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72816492020-06-17 The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe? Roelofs, Kelsey A. O’Day, Roderick Al Harby, Lamis Arora, Amit K. Cohen, Victoria M.L. Sagoo, Mandeep S. Damato, Bertil Cancers (Basel) Article Purpose: To evaluate the MOLES system for identifying malignancy in melanocytic choroidal tumors in patients treated for choroidal melanoma. Methods: Records of 615 patients treated for choroidal melanoma between January 2017 and December 2019 were reviewed. Patients were excluded if iris and/or ciliary body involvement (106 patients), inadequate fundus photography (26 patients), no images available for review (21 patients) and/or treatment was not primary (11 patients). Demographic data and AJCC TNM Stage were collected. Color fundus and autofluorescence photographs (FAF), optical coherence tomography (OCT) and B-scan ultrasounds were prospectively reviewed. MOLES scores were assigned according to five criteria: mushroom shape, orange pigment, large size, enlarging tumor and subretinal fluid. Results: A total of 451 patients (mean age, 63.9 ± 13.9 years) were included. At treatment, mean largest basal tumor diameter (LBD) and thickness were 10.3 ± 2.8 mm (range, 3.0–23.0) and 4.3 mm (range, 1.0–17.0). All but one (0.2%) had MOLES scores of ≥3. Eighty-two patients were treated after surveillance lasting a mean of 1.5 years. Initially, most (63/82; 76.8%) had a MOLES score ≥ 3. Importantly, none of the 451 tumors had a score of <2, and as such, the MOLES protocol would have indicated referral to an ocular oncologist for 100% of patients. Conclusion: The MOLES scoring system is a sensitive (99.8%) tool for indicating malignancy in melanocytic choroidal tumors (MOLES ≥ 3). If the examining practitioner can recognize the five features suggestive of malignancy, MOLES is a safe tool to optimize referral of melanocytic choroidal tumors for specialist care. MDPI 2020-05-21 /pmc/articles/PMC7281649/ /pubmed/32455720 http://dx.doi.org/10.3390/cancers12051311 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Roelofs, Kelsey A.
O’Day, Roderick
Al Harby, Lamis
Arora, Amit K.
Cohen, Victoria M.L.
Sagoo, Mandeep S.
Damato, Bertil
The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?
title The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?
title_full The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?
title_fullStr The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?
title_full_unstemmed The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?
title_short The MOLES System for Planning Management of Melanocytic Choroidal Tumors: Is It Safe?
title_sort moles system for planning management of melanocytic choroidal tumors: is it safe?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281649/
https://www.ncbi.nlm.nih.gov/pubmed/32455720
http://dx.doi.org/10.3390/cancers12051311
work_keys_str_mv AT roelofskelseya themolessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT odayroderick themolessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT alharbylamis themolessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT aroraamitk themolessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT cohenvictoriaml themolessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT sagoomandeeps themolessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT damatobertil themolessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT roelofskelseya molessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT odayroderick molessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT alharbylamis molessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT aroraamitk molessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT cohenvictoriaml molessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT sagoomandeeps molessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe
AT damatobertil molessystemforplanningmanagementofmelanocyticchoroidaltumorsisitsafe